Shandong Xinhua Pharmaceutical Company Limited Net Asset Quality Index
Shandong Xinhua Pharmaceutical Company Limited net asset quality index. Shandong Xinhua Pharmaceutical Company Limited (XIN) has a Net Asset Quality Index of 61.7% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €9.07 Billion minus total liabilities of €3.47 Billion yields net assets of €5.60 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check cash flow quality index of Shandong Xinhua Pharmaceutical Company L to evaluate the quality of earnings relative to operating cash generation.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Shandong Xinhua Pharmaceutical Company Limited (2013–2025)
Net asset quality index of Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025. This chart shows how Shandong Xinhua Pharmaceutical Company Limited's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of March 2026, the index stands at 61.7%, representing net assets of €5.60 Billion against total assets of €9.07 Billion EUR. See Shandong Xinhua Pharmaceutical Company L shareholders equity for net asset value and shareholders' equity analysis.
Shandong Xinhua Pharmaceutical Company Limited Net Asset Quality Index by Year (2013–2025)
Shandong Xinhua Pharmaceutical Company Limited net asset quality index by year from 2013 to 2025. The table below presents the year-by-year Net Asset Quality Index for Shandong Xinhua Pharmaceutical Company Limited from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Shandong Xinhua Pharmaceutical Company L market cap and net worth.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 59.4% | €5.46 Billion | €9.19 Billion | €3.73 Billion | ▲ +1.5 pp |
| 2024 | 57.8% | €5.22 Billion | €9.02 Billion | €3.80 Billion | ▲ +0.2 pp |
| 2023 | 57.6% | €4.78 Billion | €8.29 Billion | €3.51 Billion | ▲ +5.0 pp |
| 2022 | 52.6% | €4.35 Billion | €8.27 Billion | €3.92 Billion | ▲ +2.8 pp |
| 2021 | 49.8% | €3.65 Billion | €7.33 Billion | €3.68 Billion | ▲ +2.0 pp |
| 2020 | 47.8% | €3.39 Billion | €7.09 Billion | €3.70 Billion | ▼ -0.5 pp |
| 2019 | 48.3% | €3.11 Billion | €6.44 Billion | €3.33 Billion | ▲ +1.1 pp |
| 2018 | 47.3% | €2.80 Billion | €5.92 Billion | €3.12 Billion | ▼ -1.6 pp |
| 2017 | 48.9% | €2.58 Billion | €5.27 Billion | €2.69 Billion | ▲ +4.9 pp |
| 2016 | 44.0% | €2.08 Billion | €4.72 Billion | €2.64 Billion | ▼ -0.1 pp |
| 2015 | 44.2% | €1.98 Billion | €4.49 Billion | €2.51 Billion | ▼ -0.9 pp |
| 2014 | 45.0% | €1.91 Billion | €4.25 Billion | €2.33 Billion | ▼ -1.9 pp |
| 2013 | 47.0% | €1.88 Billion | €4.01 Billion | €2.13 Billion | — |